Latest Mela Sciences Inc (MELA) Headlines
MELA Sciences, Inc. (MELA) Pioneering Earlier Detection of Melanoma Is Featured in Flaherty Financial News Newsletter #41
Marketwire - Tue Mar 11, 9:35AM CDT
Fine tuning the crusade by MELA Sciences, Inc. (NASDAQ: MELA) to identify deadly melanoma earlier is featured in the March 10, 2014 issue of Flaherty Financial News Newsletter. It follows up two previous articles written four years ago.
Dermatology Diagnostic Developer, MELA Sciences, to Host Q4 Conference Call Monday, March 17, 2014 at 4:30 pm ET
Business Wire - Thu Mar 06, 8:36AM CST
MELA Sciences, Inc. (NASDAQ:MELA), developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, will release its fourth quarter and full year 2013 results on Monday, March 17, 2014, after the market's close. MELA Sciences President and CEO, Rose Crane will host a conference call that day at 4:30pm ET to review the results and provide general business update.
Rose Crane, CEO of Melanoma Diagnostics Provider, MELA Sciences, to Be Interviewed Live Today on Clear Channel Business Talk Radio DFW1190AM
Marketwire - Tue Feb 25, 10:04AM CST
MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, announced that its CEO Rose Crane will be interviewed live today by host Michael Yorba on Clear Channel Business Talk Radio's The Traders Network. All interested investors and prospective customers across the US are encouraged to tune in and listen live via Clear Channel's nationally syndicated iHeart Radio stream.
Melanoma Diagnostic Provider, MELA Sciences Receives 180-Day Extension to Meet NASDAQ Minimum Bid Price
Business Wire - Mon Feb 24, 6:55AM CST
MELA Sciences, Inc. (NASDAQ:MELA), (the Company) developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, has filed a Form 8-K providing full details of a 180-day grace period it has received from NASDAQ to fulfill the minimum $1.00 bid price requirement. The extension gives the Company until August 18, 2014 to regain compliance.
MELA Sciences Completes Private Placement to Institutional Investors and MELA Sciences Directors
Business Wire - Wed Feb 05, 4:15PM CST
MELA Sciences, Inc. (NASDAQ:MELA), (the Company) developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, today announced the closing of its previously announced $12.45 million private placement of convertible preferred stock, common stock warrants and common stock. Net proceeds to the Company from this offering are approximately $11.5 million.
Kakamega Small-Scale Farmers Get Sh29m World Bank Boost
by Hilton Otenyo - All Africa Global Media - Tue Feb 04, 4:43AM CST
SMALL scale farmers in Kakamega county have received Sh29 million through a World Bank funded project to boost income and reduce poverty.
Melanoma Diagnostic Provider, MELA Sciences Provides Details of Recent $12.45 Million Private Placement
Business Wire - Mon Feb 03, 6:55AM CST
MELA Sciences, Inc. (NASDAQ:MELA), (the Company) developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, today filed a Form 8-K providing full details from its recent Private Placement. Following is the text of the details relating to the private placement that were provided in the Form 8-K.
CORRECTING and REPLACING Melanoma Diagnostic Provider, MELA Sciences, to Raise $12.45 Million in Private Placement to Institutional Investors and MELA Sciences Directors
Business Wire - Fri Jan 31, 1:03PM CST
Second graph, second sentence of release should read ...13,297,297 shares of common stock at an exercise price of $0.74. (sted ...11,714,286 shares of common stock at an exercise price of $0.74.).
Melanoma Diagnostic Provider, MELA Sciences, to Raise $12.45 Million in Private Placement to Institutional Investors and MELA Sciences Directors
Business Wire - Fri Jan 31, 8:44AM CST
MELA Sciences, Inc. (NASDAQ: MELA), (the Company) developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, today announced it has entered into definitive agreements with institutional investors and management for the private placement of $12.45 million of the Company's convertible preferred stock, common stock warrants and common stock. The investors in the transaction were funds managed by Sabby Management, LLC, which comprise the Company's largest existing beneficial shareholder, and Broadfin Capital, LLC. In conjunction with the financing, MELA Sciences' directors have agreed to purchase $150,000 in restricted common stock priced at $0.74 per share, yesterday's closing bid price for MELA's common stock.
Dermatologist Highlights Medical Benefits of MelaFind Device in Aiding Melanoma Diagnosis at Most Treatable Stage
Business Wire - Thu Jan 30, 6:55AM CST
MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, hosted a MelaFind(R) workshop during the 10th Annual Maui Derm Conference in Hawaii. The conference seeks to increase physicians' knowledge of developments in medical and cosmetic dermatology.
Medical Diagnostic Developer MELA Sciences to Present at SeeThruEquity Microcap Conf. Feb. 6 in NYC and to Exhibit at Maui Dermatology Conf. Jan. 26-30
Business Wire - Mon Jan 27, 6:55AM CST
MELA Sciences, Inc. (NASDAQ:MELA), developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced its CEO, Rose Crane, will present at the SeeThruEquity Winter Microcap Investor Conference on February 6, 2014 at 9:30 am ET in New York. Ms. Crane; Robert Coradini, Chairman; Mary Phellan, Controller; and Diana Garcia Redruello, head of the MelaFind Commercial Team will be available for one-on-one meetings that day.
MELA Sciences Announces the Results of its Third Clinical Advisory Meeting and the Four Clinical Posters Presented at the Winter Clinical Dermatology Conference
Business Wire - Wed Jan 22, 6:55AM CST
MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced the results of its third company-sponsored Clinical Advisory meeting hosted during the Winter Clinical Dermatology Conference in Hawaii where technical advancements of MelaFind(R) and future technology development opportunities were discussed and user's validated its clinical use. MELA Sciences also displayed four clinical posters presentations at the conference, which took place from January 17 - 22, 2014.
Melanoma Diagnostic Developer MELA Sciences Hosts Clinical Advisory Meeting & Exhibits Four Clinical Posters at Winter Clinical Dermatology Conference - January 17 - 22
Business Wire - Thu Jan 16, 6:55AM CST
MELA Sciences, Inc. (NASDAQ:MELA), developer of MelaFind(R), an FDA-approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, will host its third company-sponsored Clinical Advisory meeting for select dermatologists and key opinion leaders in melanoma and provide recent clinical findings at the Winter Clinical Dermatology Conference being held January 17-22 at the Fairmont Orchid Hotel, Kona Coast, Hawaii.
MELA Sciences Appoints Healthcare Executive Jeff O'Donnell as Director and Streamlines Board to Support Refocused Go-to-Market Strategy
Business Wire - Thu Jan 02, 7:00AM CST
MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced a realignment of its Board's composition and size to better support the Company's refocused go-to-market strategy for MelaFind. MELA also announced the resignation of Richard I. Steinhart, SVP Finance and Chief Financial Officer, effective December 31st. Mr. Steinhart has served as MELA's CFO since 2006. A search process has been initiated with an executive recruiter to secure a replacement. Rose Crane, MELA's CEO, will handle the CFO responsibilities on an interim basis with the assistance of the company's controller.
MELA Sciences Reports Positive Reception for its Optical Melanoma Diagnostic Device at Clinical Advisory Meeting and Mount Sinai Winter Dermatology Symposium
Business Wire - Mon Dec 09, 11:47AM CST
MELA Sciences, Inc. (NASDAQ: MELA) designer and developer of MelaFind(R), an FDA approved non-invasive optical device that assists dermatologists in the diagnosis of melanoma, received positive dermatologist feedback from its second Clinical Advisory Meeting held in conjunction with the 16th Annual Mount Sinai Winter Dermatology Symposium last week.
Melanoma Diagnostics Leader, MELA Sciences, Inc., Participates in Skin Cancer Diagnostic Workshop with Leading German Dermatologists, Hosted by Germany's Augsburg Clinic
Business Wire - Fri Dec 06, 6:56AM CST
MELA Sciences, Inc. (NASDAQ:MELA), designer and developer of MelaFind(R), an FDA and CE Mark approved non-invasive optical device that assists dermatologists in diagnosing melanoma at its most curable stage, participated in a two-day hands-on skin cancer diagnostics workshop in Augsburg, Germany, where leading dermatologists examined "high-risk" melanoma patients with MelaFind(R) and also participated in an imaging devices exhibit.
Melanoma Diagnostics Leader, MELA Sciences, Hosts Clinical Advisory Meeting Friday, Dec. 6th in Conjunction with Mount Sinai Winter Dermatology Symposium
Business Wire - Thu Dec 05, 6:56AM CST
MELA Sciences, Inc. (NASDAQ:MELA) designer and developer of MelaFind(R), an FDA approved non-invasive optical device that assists dermatologists in diagnosing melanoma at its most curable stage, announces the Company will participate in the 16th Annual Mount Sinai Winter Dermatology Symposium in New York City, December 6-8, 2013. In conjunction with the Symposium, MELA will also host its second Clinical Advisory Meeting on Friday, December 6, 2013.
Solta Medical (SLTM) in Focus: Stock Moves Up 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 03, 6:57AM CST
Solta Medical, Inc. (SLTM) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
MELA Sciences, a Leader in Melanoma Diagnostics, Appoints Rose Crane as President and Chief Executive Officer and a Director, Effective as of Monday, November 11th
GlobeNewswire - Wed Nov 06, 3:05PM CST
MELA Sciences, Inc. (Nasdaq:MELA), the medical device company that has developed and is commercializing MelaFind(R), an optical diagnostic device using proprietary technology that enables dermatologists to "see" below the surface of a patient's skin to aid in the diagnosis of melanoma, today announced that the Company has appointed Rose Crane as its President and Chief Executive Officer and a director, effective as of November 11, 2013. At such time Interim CEO, Robert Coradini, will assume the Chairman's role and thereafter is planned to provide ongoing active consulting while current Chairman, David Stone, will resume his director's role on the Board.
MELA Sciences, Inc. (MELA) Pioneering Earlier Detection of Melanoma Is Featured in Flaherty Financial News Newsletter #41
Marketwire - Tue Mar 11, 9:35AM CDT
Fine tuning the crusade by MELA Sciences, Inc. (NASDAQ: MELA) to identify deadly melanoma earlier is featured in the March 10, 2014 issue of Flaherty Financial News Newsletter. It follows up two previous articles written four years ago.
Dermatology Diagnostic Developer, MELA Sciences, to Host Q4 Conference Call Monday, March 17, 2014 at 4:30 pm ET
Business Wire - Thu Mar 06, 8:36AM CST
MELA Sciences, Inc. (NASDAQ:MELA), developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, will release its fourth quarter and full year 2013 results on Monday, March 17, 2014, after the market's close. MELA Sciences President and CEO, Rose Crane will host a conference call that day at 4:30pm ET to review the results and provide general business update.
Rose Crane, CEO of Melanoma Diagnostics Provider, MELA Sciences, to Be Interviewed Live Today on Clear Channel Business Talk Radio DFW1190AM
Marketwire - Tue Feb 25, 10:04AM CST
MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, announced that its CEO Rose Crane will be interviewed live today by host Michael Yorba on Clear Channel Business Talk Radio's The Traders Network. All interested investors and prospective customers across the US are encouraged to tune in and listen live via Clear Channel's nationally syndicated iHeart Radio stream.
Melanoma Diagnostic Provider, MELA Sciences Receives 180-Day Extension to Meet NASDAQ Minimum Bid Price
Business Wire - Mon Feb 24, 6:55AM CST
MELA Sciences, Inc. (NASDAQ:MELA), (the Company) developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, has filed a Form 8-K providing full details of a 180-day grace period it has received from NASDAQ to fulfill the minimum $1.00 bid price requirement. The extension gives the Company until August 18, 2014 to regain compliance.
MELA Sciences Completes Private Placement to Institutional Investors and MELA Sciences Directors
Business Wire - Wed Feb 05, 4:15PM CST
MELA Sciences, Inc. (NASDAQ:MELA), (the Company) developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, today announced the closing of its previously announced $12.45 million private placement of convertible preferred stock, common stock warrants and common stock. Net proceeds to the Company from this offering are approximately $11.5 million.
Kakamega Small-Scale Farmers Get Sh29m World Bank Boost
by Hilton Otenyo - All Africa Global Media - Tue Feb 04, 4:43AM CST
SMALL scale farmers in Kakamega county have received Sh29 million through a World Bank funded project to boost income and reduce poverty.
Melanoma Diagnostic Provider, MELA Sciences Provides Details of Recent $12.45 Million Private Placement
Business Wire - Mon Feb 03, 6:55AM CST
MELA Sciences, Inc. (NASDAQ:MELA), (the Company) developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, today filed a Form 8-K providing full details from its recent Private Placement. Following is the text of the details relating to the private placement that were provided in the Form 8-K.
CORRECTING and REPLACING Melanoma Diagnostic Provider, MELA Sciences, to Raise $12.45 Million in Private Placement to Institutional Investors and MELA Sciences Directors
Business Wire - Fri Jan 31, 1:03PM CST
Second graph, second sentence of release should read ...13,297,297 shares of common stock at an exercise price of $0.74. (sted ...11,714,286 shares of common stock at an exercise price of $0.74.).
Melanoma Diagnostic Provider, MELA Sciences, to Raise $12.45 Million in Private Placement to Institutional Investors and MELA Sciences Directors
Business Wire - Fri Jan 31, 8:44AM CST
MELA Sciences, Inc. (NASDAQ: MELA), (the Company) developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, today announced it has entered into definitive agreements with institutional investors and management for the private placement of $12.45 million of the Company's convertible preferred stock, common stock warrants and common stock. The investors in the transaction were funds managed by Sabby Management, LLC, which comprise the Company's largest existing beneficial shareholder, and Broadfin Capital, LLC. In conjunction with the financing, MELA Sciences' directors have agreed to purchase $150,000 in restricted common stock priced at $0.74 per share, yesterday's closing bid price for MELA's common stock.
Dermatologist Highlights Medical Benefits of MelaFind Device in Aiding Melanoma Diagnosis at Most Treatable Stage
Business Wire - Thu Jan 30, 6:55AM CST
MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, hosted a MelaFind(R) workshop during the 10th Annual Maui Derm Conference in Hawaii. The conference seeks to increase physicians' knowledge of developments in medical and cosmetic dermatology.
Medical Diagnostic Developer MELA Sciences to Present at SeeThruEquity Microcap Conf. Feb. 6 in NYC and to Exhibit at Maui Dermatology Conf. Jan. 26-30
Business Wire - Mon Jan 27, 6:55AM CST
MELA Sciences, Inc. (NASDAQ:MELA), developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced its CEO, Rose Crane, will present at the SeeThruEquity Winter Microcap Investor Conference on February 6, 2014 at 9:30 am ET in New York. Ms. Crane; Robert Coradini, Chairman; Mary Phellan, Controller; and Diana Garcia Redruello, head of the MelaFind Commercial Team will be available for one-on-one meetings that day.
MELA Sciences Announces the Results of its Third Clinical Advisory Meeting and the Four Clinical Posters Presented at the Winter Clinical Dermatology Conference
Business Wire - Wed Jan 22, 6:55AM CST
MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced the results of its third company-sponsored Clinical Advisory meeting hosted during the Winter Clinical Dermatology Conference in Hawaii where technical advancements of MelaFind(R) and future technology development opportunities were discussed and user's validated its clinical use. MELA Sciences also displayed four clinical posters presentations at the conference, which took place from January 17 - 22, 2014.
Melanoma Diagnostic Developer MELA Sciences Hosts Clinical Advisory Meeting & Exhibits Four Clinical Posters at Winter Clinical Dermatology Conference - January 17 - 22
Business Wire - Thu Jan 16, 6:55AM CST
MELA Sciences, Inc. (NASDAQ:MELA), developer of MelaFind(R), an FDA-approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, will host its third company-sponsored Clinical Advisory meeting for select dermatologists and key opinion leaders in melanoma and provide recent clinical findings at the Winter Clinical Dermatology Conference being held January 17-22 at the Fairmont Orchid Hotel, Kona Coast, Hawaii.
MELA Sciences Appoints Healthcare Executive Jeff O'Donnell as Director and Streamlines Board to Support Refocused Go-to-Market Strategy
Business Wire - Thu Jan 02, 7:00AM CST
MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced a realignment of its Board's composition and size to better support the Company's refocused go-to-market strategy for MelaFind. MELA also announced the resignation of Richard I. Steinhart, SVP Finance and Chief Financial Officer, effective December 31st. Mr. Steinhart has served as MELA's CFO since 2006. A search process has been initiated with an executive recruiter to secure a replacement. Rose Crane, MELA's CEO, will handle the CFO responsibilities on an interim basis with the assistance of the company's controller.
MELA Sciences Reports Positive Reception for its Optical Melanoma Diagnostic Device at Clinical Advisory Meeting and Mount Sinai Winter Dermatology Symposium
Business Wire - Mon Dec 09, 11:47AM CST
MELA Sciences, Inc. (NASDAQ: MELA) designer and developer of MelaFind(R), an FDA approved non-invasive optical device that assists dermatologists in the diagnosis of melanoma, received positive dermatologist feedback from its second Clinical Advisory Meeting held in conjunction with the 16th Annual Mount Sinai Winter Dermatology Symposium last week.
Melanoma Diagnostics Leader, MELA Sciences, Inc., Participates in Skin Cancer Diagnostic Workshop with Leading German Dermatologists, Hosted by Germany's Augsburg Clinic
Business Wire - Fri Dec 06, 6:56AM CST
MELA Sciences, Inc. (NASDAQ:MELA), designer and developer of MelaFind(R), an FDA and CE Mark approved non-invasive optical device that assists dermatologists in diagnosing melanoma at its most curable stage, participated in a two-day hands-on skin cancer diagnostics workshop in Augsburg, Germany, where leading dermatologists examined "high-risk" melanoma patients with MelaFind(R) and also participated in an imaging devices exhibit.
Melanoma Diagnostics Leader, MELA Sciences, Hosts Clinical Advisory Meeting Friday, Dec. 6th in Conjunction with Mount Sinai Winter Dermatology Symposium
Business Wire - Thu Dec 05, 6:56AM CST
MELA Sciences, Inc. (NASDAQ:MELA) designer and developer of MelaFind(R), an FDA approved non-invasive optical device that assists dermatologists in diagnosing melanoma at its most curable stage, announces the Company will participate in the 16th Annual Mount Sinai Winter Dermatology Symposium in New York City, December 6-8, 2013. In conjunction with the Symposium, MELA will also host its second Clinical Advisory Meeting on Friday, December 6, 2013.
Solta Medical (SLTM) in Focus: Stock Moves Up 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 03, 6:57AM CST
Solta Medical, Inc. (SLTM) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
MELA Sciences, a Leader in Melanoma Diagnostics, Appoints Rose Crane as President and Chief Executive Officer and a Director, Effective as of Monday, November 11th
GlobeNewswire - Wed Nov 06, 3:05PM CST
MELA Sciences, Inc. (Nasdaq:MELA), the medical device company that has developed and is commercializing MelaFind(R), an optical diagnostic device using proprietary technology that enables dermatologists to "see" below the surface of a patient's skin to aid in the diagnosis of melanoma, today announced that the Company has appointed Rose Crane as its President and Chief Executive Officer and a director, effective as of November 11, 2013. At such time Interim CEO, Robert Coradini, will assume the Chairman's role and thereafter is planned to provide ongoing active consulting while current Chairman, David Stone, will resume his director's role on the Board.
